



# STAAR SURGICAL CO

## FORM 8-K

(Current Report Filing)

Filed 02/28/24 for the Period Ending 02/26/24

Address 1911 WALKER AVE, MONROVIA, CA, 91016  
Telephone (727) 384-2323  
CIK 0000718937  
Symbol STAA  
SIC Code 3851 - Ophthalmic Goods  
Fiscal Year 12/30

Powered by **barchart**

<https://www.barchart.com/solutions>

© Copyright 2022, Barchart.com, Inc. All Rights Reserved.

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of  
1934**

**Date of report (Date of earliest event reported): February 26,  
2024**

**STAAR Surgical Company  
(Exact Name of Registrant as Specified in  
Charter)**

Delaware  
(State or Other Jurisdiction  
of Incorporation)

0-11634  
(Commission File Number)

95-3797439  
(IRS Employer  
Identification No.)

25651 Atlantic Ocean Drive  
Lake Forest, California  
(Address of Principal Executive Offices)

92630  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 626-303-7902**

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class  
Common

Trading Symbol(s)  
STAA

Name of each exchange on which registered  
NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On February 26, 2024, STAAR Surgical Company (the “Company”) held a conference call to discuss its financial results for the quarter and year ended December 29, 2023. A transcript of the conference call is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report and Exhibit 99.1 shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

**Item 9.01 Financial Statements and Exhibits**

Exhibit No.	Description
99.1	<a href="#">Transcript of conference call of the Company held on February 26, 2024.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**STAAR Surgical Company**

February 28, 2024

By: /s/ Tom Frinzi  
Thomas G. Frinzi  
President and Chief Executive Officer

---

